Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Macimorelin (Macrilen) vs Vosoritide (Voxzogo)
An educational, source-based comparison of Macimorelin (Macrilen) and Vosoritide (Voxzogo) — how each peptide works, what it's researched for, and what to know before going deeper.
Oral ghrelin agonist for diagnosing adult growth hormone deficiency.
Oral ghrelin receptor (GHSR-1a) agonist that stimulates pituitary GH release; peak GH response is measured to evaluate adult GH deficiency.
- Diagnostic test for adult GH deficiency
- • FDA-approved.
- • Avoid with QT-prolonging drugs.
- • Hold strong CYP3A4 inducers prior to test.
C-type natriuretic peptide analog for achondroplasia.
Modified C-type natriuretic peptide (CNP) analog that binds NPR-B, antagonizing overactive FGFR3 signaling in the growth plate to increase endochondral bone growth in children with achondroplasia.
- Achondroplasia in children ≥5 years (now ≥4 months)
- • FDA-approved.
- • Transient blood pressure decrease; ensure adequate hydration/food before dosing.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Macimorelin (Macrilen) | Macimorelin vs ITT for AGHD | JCEM | 2018 | Non-inferior diagnostic accuracy to insulin tolerance test with better tolerability. |
| Vosoritide (Voxzogo) | Vosoritide Phase 3 trial | Lancet | 2020 | Increased annualized growth velocity vs placebo in children with achondroplasia. |
Side-effect & safety grid
- FDA-approved.
- Avoid with QT-prolonging drugs.
- Hold strong CYP3A4 inducers prior to test.
- FDA-approved.
- Transient blood pressure decrease; ensure adequate hydration/food before dosing.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Macimorelin (Macrilen) vs Vosoritide (Voxzogo) — Key differences
- Class: Macimorelin (Macrilen) is classified as GH Secretagogue · Diagnostics, while Vosoritide (Voxzogo) is CNP Analog · Skeletal Growth.
- Primary research focus: Macimorelin (Macrilen) — diagnostic test for adult gh deficiency; Vosoritide (Voxzogo) — achondroplasia in children ≥5 years (now ≥4 months).
- Tag: FDA-Approved · Diagnostics vs FDA-Approved · Genetic.